Measles mumps and rubella virus vaccine (Priorix)

Drug Profile

Measles mumps and rubella virus vaccine (Priorix)

Alternative Names: 209762; GSK-209762; MMR vaccine - Bio-Manguinhos; MMR vaccine - GlaxoSmithKline; Priorix

Latest Information Update: 03 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Measles vaccines; Rubella vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Measles; Mumps; Rubella

Most Recent Events

  • 26 Oct 2016 Immunogenicity and adverse events data from a phase III trial in Rubella, Measles and Mumps released by GlaxoSmithKline
  • 01 Jul 2016 The Immunobiological Technology Institute and GlaxoSmithKline complete a phase III trial for Measles, Mumps and Rubella (In infants, Prevention) in Brazil (NCT01991899)
  • 01 Dec 2015 GlaxoSmithKline completes a phase III trial in Measles, mumps and rubella (in infants, prevention) in Estonia, Finland, Puerto Rico, Spain and USA (NCT02184572)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top